Biofil Chemicals & Pharmaceuticals Ltd P/E Ratio

The P/E Ratio of Biofil Chemicals & Pharmaceuticals Ltd is 147.3 as of 26 Jul 9.00 AM .a1#The P/E Ratio of Biofil Chemicals & Pharmaceuticals Ltd changed from 22 on March 2019 to 121.9 on March 2023 . This represents a CAGR of 40.84% over 5 years. a1#The Latest Trading Price of Biofil Chemicals & Pharmaceuticals Ltd is ₹ 64.83 as of 26 Jul 15:30 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.3 to 27.2 in 5 years. This represents a CAGR of -0.79%a1# The PE Ratio of Automobile industry is 18.9. The PE Ratio of Finance industry is 23.0. The PE Ratio of IT - Software industry is 29.1. The PE Ratio of Pharmaceuticals industry is 38.6. The PE Ratio of Retail industry is 143.1. The PE Ratio of Textiles industry is 24.3. In 2024a1#The Market Cap of Biofil Chemicals & Pharmaceuticals Ltd changed from ₹ 10.75 crore on March 2019 to ₹ 67.42 crore on March 2023 . This represents a CAGR of 44.37% over 5 years. a1#The Revenue of Biofil Chemicals & Pharmaceuticals Ltd changed from ₹ 12.32 crore to ₹ 15.61 crore over 8 quarters. This represents a CAGR of 12.56% a1#The EBITDA of Biofil Chemicals & Pharmaceuticals Ltd changed from ₹ 0.39 crore to ₹ 0.37 crore over 8 quarters. This represents a CAGR of -2.60% a1#The Net Pr of Biofil Chemicals & Pharmaceuticals Ltd changed from ₹ 0.21 crore to ₹ 0.25 crore over 8 quarters. This represents a CAGR of 9.11% a1#The Dividend Payout of Biofil Chemicals & Pharmaceuticals Ltd changed from 0 % on March 2019 to 0 % on March 2023 . This represents a CAGR of 0.0% over 5 years. a1#

Biofil Chemicals & Pharmaceuticals Limited (BCPL) was incorporated as a Private Limited Company on 4 Jan.'85 for manufacturing and trading of Pharmaceuticals products. Later on, the Company was converted into a Public Limited Company on 7 May '92. The Company deals in providing job work facility in respect of manufacturing of pharmaceuticals drug. It runs the business via two unit viz Pharmaceutical Division & Chemicals Division. In Feb.'96, the company had come out with a rights-cum-public issue at a premium of Rs 7.50 and at a premium of Rs 12.50 respectively, both aggregating Rs 23.21 cr, to part-finance its expansion and diversification into bulk drugs and pharmaceutical formulations. The company currently manufactures pharmaceutical formulations like injections, capsules, eye-drops and dry syrups at its plant located in Indore. BCPL's new unit was set up at Pithampur in Madhya Pradesh at a project costing Rs 39.75 cr. The Company entered into business partnership with HLL Lifecare Limited (Formerly Hindustan Latex Ltd) an undertaking of Government of India. As per the agreed terms it provided manufacturing facility to HLL Lifecare Limited for manufacturing of Iron and Folic Acid Tablets (IFA) and other Pharmaceuticals products as required by HLL. Presently, the Company is flourishing business activates at Pithampur, in Madhya Pradesh. Now Company is not only dealing in the pharmaceutical product but has diversified its business activity in producing plastic products required for packing of pharmaceutical product and other plastic products.